[Expert opinions on clinical application of interferon-γ release assay of Mycobacterium tuberculosis (2021 edition)].

Interferon-γ release assay (IGRA) is an in vitro immunological technique for Mycobacterium tuberculosis diagnosis, which is recommended by the World Health Organization. As one of the auxiliary diagnosis methods for active tuberculosis in diagnostic criteria of China, the method and technique have been developed in recent years, and a wealth of clinical applied experience has been accumulated in the clinical application in China. Based on the "Opinions of applications of IGRA in China (2014 edition)" issued by Chinese Society for Tuberculosis, Chinese Medical Association, it was revised and improved according to the latest developments and clinical experience, and the expert opinions were presented in six parts: principles and technical advances, quality control, application of latent tuberculosis infection diagnosis, auxiliary diagnosis of active tuberculosis, application in special populations, and the influence of common drugs on IGRA results, with a view to providing guidance for the clinical application of IGRA in China.γ-干扰素释放试验（IGRA）是世界卫生组织推荐的用于诊断结核分枝杆菌感染的体外免疫学方法，也是我国肺结核诊断标准中用于活动性结核辅助诊断的手段之一。近年，IGRA的方法和技术不断发展和更新，在国内的临床应用中也积累了丰富的经验。本专家意见在中华医学会结核病学分会2014年编写的《γ-干扰素释放试验在中国应用的建议》基础上，根据最新发展和临床经验进行修订和完善，从原理和技术进展、质量控制、结核潜伏感染诊断的应用、活动性肺结核辅助诊断应用、特殊人群中的应用以及常见药物对IGRA结果的影响六个部分提出专家意见，以期为IGRA在中国的临床应用提供指导。.